Predictive value of galectin-3 for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort

International Journal of Cardiology

Volumn 192, Issue , 2015, Pages 33-39

  Jagodzinski, Annika ^a,b   Havulinna, Aki S ^c   Appelbaum, Sebastian ^a,b   Zeller, Tanja ^a,b   Jousilahti, Pekka ^c   Skytte Johanssen, Silke ^a   Hughes, Maria F ^a,b,d,e   Blankenberg, Stefan ^a,b   Salomaa, Veikko ^c  

^a UNIVERSITY OF HAMBURG   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; GALECTIN 3; BIOLOGICAL MARKER; GALECTIN-3, HUMAN;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; DIABETES MELLITUS; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HAZARD RATIO; HEART DEATH; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; MALE; MORTALITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; SMOKING; VALVULAR HEART DISEASE; BLOOD; CARDIOVASCULAR DISEASES; MIDDLE AGED; REGISTER;

ADULT; AGED; BIOMARKERS; CARDIOVASCULAR DISEASES; FEMALE; GALECTIN 3; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REGISTRIES;

EID: 84930946739     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.05.040     Document Type: Article

References (25)

1. D.M. Lloyd-Jones, Y. Hong, and D. Labarthe Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond Circulation 121 4 2010 586 613
2. T.A. Pearson, L.P. Palaniappan, and N.T. Artinian American Heart Association guide for improving cardiovascular health at the community level, 2013 update: a scientific statement for public health practitioners, healthcare providers, and health policy makers Circulation 127 16 2013 1730 1753
3. D.J. Lok, P. Van Der Meer, and P.W. de la Porte Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study Clin. Res. Cardiol. 99 5 2010 323 328
4. R.A. de Boer, A.A. Voors, P. Muntendam, W.H. van Gilst, and D.J. van Veldhuisen Galectin-3: a novel mediator of heart failure development and progression Eur. J. Heart Fail. 11 9 2009 811 817
5. N.C. Henderson, A.C. Mackinnon, and S.L. Farnworth Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis Am. J. Pathol. 172 2 2008 288 298
6. G.J. Fermann, C.J. Lindsell, and A.B. Storrow Galectin 3 complements BNP in risk stratification in acute heart failure, Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22, Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study Biomarkers 1373 17 8 2012 706 713
7. J.M. Cheng, K.M. Akkerhuis, and L.C. Battes Biomarkers of heart failure with normal ejection fraction: a systematic review 2013 Eur. J Heart Fail
8. U.C. Sharma, S. Pokharel, and T.J. van Brakel Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction Circulation 110 19 2004 3121 3128
9. J.E. Ho, C. Liu, and A. Lyass Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community J. Am. Coll. Cardiol. 60 14 2012 1249 1256
10. E. Vartiainen, T. Laatikainen, and M. Peltonen Thirty-five-year trends in cardiovascular risk factors in Finland Int. J. Epidemiol. 39 2 2010 504 518
11. P. Pajunen, H. Koukkunen, and M. Ketonen The validity of the Finnish Hospital Discharge Register and Causes of Death Register data on coronary heart disease Eur. J. Cardiovasc. Prev. Rehabil. 12 2 2005 132 137
12. M. Mahonen, A. Jula, and K. Harald The validity of heart failure diagnoses obtained from administrative registers Eur. J. Prev. Cardiol. 20 2 2013 254 259
13. S. Blankenberg, T. Zeller, and O. Saarela Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project Circulation 121 22 2010 2388 2397
14. L.A. Inker, C.H. Schmid, and H. Tighiouart Estimating glomerular filtration rate from serum creatinine and cystatin C N. Engl. J. Med. 367 1 2012 20 29
15. K. Pyorala, J.T. Salonen, and T. Valkonen Trends in coronary heart disease mortality and morbidity and related factors in Finland Cardiology 72 1-2 1985 35 51
16. S. van Buuren, and K. Groothuis-Oudshoorn Mice: multivariate imputation by chained equations in R J. Stat. Softw. 45 3 2011
17. M.J. Pencina, R.B. D'Agostino Sr., R.B. D'Agostino Jr., and R.S. Vasan Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond Stat. Med. 27 2 2008 157 172 (discussion 207-12)
18. N.R. Cook Use and misuse of the receiver operating characteristic curve in risk prediction Circulation 115 7 2007 928 935
19. E.W. Grandin, P. Jarolim, and S.A. Murphy Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22 Clin. Chem. 58 1 2012 267 273
20. T.H. Tsai, P.H. Sung, and L.T. Chang Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention J. Atheroscler. Thromb. 19 12 2012 1073 1082
21. D.J. Lok, S.I. Lok, and P.W. Bruggink-Andre de la Porte Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure Clin. Res. Cardiol. 102 2 2013 103 110
22. R.A. de Boer, D.J. Lok, and T. Jaarsma Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction Ann. Med. 43 1 2011 60 68
23. G.M. Felker, M. Fiuzat, and L.K. Shaw Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study Circ. Heart Fail. 5 1 2012 72 78
24. A.R. van der Velde, L. Gullestad, and T. Ueland Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH Circ. Heart Fail. 6 2 2013 219 226
25. G. de Couto, M. Ouzounian, and P.P. Liu Early detection of myocardial dysfunction and heart failure Nat. Rev. Cardiol. 7 6 2010 334 344